Tricida — Investor Presentation (March 2021)
35 slides from Tricida's investor presentation, Mar 2, 2021
Slide 1: Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease
Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation March 2021 Exhibit 99.1
Slide 2: Forward Looking Statements
2 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Examples of such statements include our plans, beliefs
Slide 3: Our Goals for Veverimer
3*Veverimer is not yet approved by the FDA First and ONLY FDA-Approved Therapy Significant unmet medical need to treat chronic metabolic acidosis Improve How Patients Feel and Function Enhance physical functioning and physical functioning-related quality of life Disease Modifying Slow CKD progressio
Slide 4: Veverimer Is Being Developed to Treat Metabolic Acidosis and Potentially Slow CKD Progression
4 Veverimer Is Being Developed to Treat Metabolic Acidosis and Potentially Slow CKD Progression Completed Phase 3 long-term safety and durability of effect trial Phase 3 trial results published Phase 3 long-term safety and durability of effect trial results published NDA filed with review granted th
Slide 5: Metabolic Acidosis is Commonly Caused by Kidney Disease
5 Daily Metabolism Metabolic Acidosis is Commonly Caused by Kidney Disease Kraut. Nat Rev Nephrol. 2010;6(5):274; KDIGO Clinical Practice Guidelines 2012. Serum Bicarbonate Levels FallDiseased Kidneys Lose Capacity to Excrete Acid Acid is generated from dietary sources and daily metabolism Diseased
Slide 6: Metabolic Acidosis Is a Serious Condition Needs to Be Treated
6 Metabolic Acidosis Is a Serious Condition Harmful Needs to Be Treated 0% 20% 40% 60% 80% 100% Dobre 2013 Tangri 2020 TRCA-301 Tangri 2019 < 3% < 10% 15% < 6% % o f P at ie nt s R ec ei vi ng O ra l A lk al i T he ra pyThe Majority of Patients with Metabolic Acidosis are NOT treated No FDA Approved
Slide 7: Multiple Academic Studies Show Impact of Raising Serum Bicarbonate Levels
7 Oral alkali Dietary intervention Multiple Academic Studies Show Impact of Raising Serum Bicarbonate Levels Navaneethan et al., CJASN, 2019; 14: 1011-1020. Meta Analysis Shows Slower Decline in eGFR at the End of Study Period with Oral Alkali Supplementation or Reduction of Dietary Acid Intake
Slide 8: Each mEq/L Increase in Serum Bicarbonate Reduces the Risk of CKD Progression
8 Observational Data Show that Each 1 mEq/L Increase in Serum Bicarbonate Reduces the Risk of CKD Progression Tangri et al., NKF SCM, 2018. Data on file. Predictive MA Model Time-Dependent Predictive Model Data source Sunnybrook Hospital, Canada Nationally recognized database, U.S. Sample size (N) 2
Slide 9: Veverimer: Designed to Bind and Remove Acid from the GI Tract
Veverimer: Designed to Bind and Remove Acid from the GI Tract to Raise Serum Bicarbonate to Treat Metabolic Acidosis and Slow CKD Progression
Slide 10: Veverimer: Designed to Bind and Remove HCl with High Capacity and Selectivity
10GI: Gastrointestinal. HCl: Hydrochloric acid. *Veverimer’s maximum theoretical HCl binding capacity is approximately 10 mEq/gram. Excreted, resulting in removal of HCl* Binds protons (H+) and then selectively binds chloride (Cl–) in the GI tract Excretion in Feces O ra l I ng es tio n A ci d B in
Slide 11: Veverimer: Ease of Administration
11 Veverimer: Ease of Administration* Once-a-day dosing Orally administered as a suspension in water 3 g, 6 g or 9 g dose sizes No observed drug-drug interactions** 2 oz. Water *Targeted profile if approved ** Data on file
Slide 12: Veverimer: Clinical Development Program and Regulatory Path
Veverimer: Clinical Development Program and Regulatory Path
Slide 13: Veverimer Clinical Development Program
13 Veverimer Clinical Development Program* QD = Once daily. * In addition, a randomized, placebo-controlled Phase 1/2 trial of veverimer in patients with metabolic acidosis and CKD was conducted in 2017 and is published, Bushinsky et al., 2018, CJSAN. Wesson DE et al., Lancet 2019; 393: 1417-27. Wes
Slide 14: Summary of FDA Interactions for the Veverimer NDA
14 Summary of FDA Interactions for the Veverimer NDA* • Submitted NDA for review through the Accelerated Approval Program August 2019 • Received CRL August 2020 • Held End-of-Review Type A meeting with FDA Division of Cardiology and Nephrology October 2020 • Submitted FDRR to the Office of New Drugs
Slide 15: Several Potential Pathways to Approval of Veverimer
15 Tricida Believes There Are Several Potential Pathways to Approval of Veverimer • VALOR-CKD stopped early for administrative reasons and yields positive data: – Slowing of CKD progression – Physical functioning Potential Approval Pathway Potential Timing of Data Based on Current Event Accumulation
Slide 16: Completed Phase 3 Clinical Trial: TRCA-301/TRCA-301E
Completed Phase 3 Clinical Trial: TRCA-301/TRCA-301E
Slide 17: TRCA-301 and TRCA-301E Trial Results Published in The Lancet
17 Veverimer: TRCA-301 and TRCA-301E Trial Results Published in The Lancet TRCA-301 Results TRCA-301E Results Wesson DE et al., Lancet 2019; 393: 1417-27. Wesson DE et al., Lancet 2019; 394: 396-406.
Slide 18: Baseline Disease Characteristics of Subjects Enrolled in TRCA-301
18 Baseline Disease Characteristics of Subjects Enrolled in TRCA-301 Veverimer N=124 Placebo N=93 Baseline eGFR, mean 29 mL/min/1.73m2 28 mL/min/1.73m2 Baseline serum bicarbonate, mean 17 mEq/L 17 mEq/L Selected Medical History CKD 100% 100% Hypertension 97% 97% Diabetes 61% 70% Left ventricular hyp
Slide 19: Veverimer-Treated Subjects Experienced Mean Increase in Serum Bicarbonate of 4.5 mEq/L
19 TRCA-301 Veverimer-Treated Subjects Experienced a Mean Increase from Baseline in Serum Bicarbonate of 4.5 mEq/L Tricida Believes in the Strength of the Data from its TRCA-301/301E Clinical Trial BL: Baseline. W: Week. Error bars: Standard error of the mean. DD50: Death, dialysis or ≥50% reduction
Slide 20: Veverimer: TRCA-301/301E Safety Summary
20 Veverimer: TRCA-301/301E Safety Summary TRCA-301 TRCA-301E Veverimer (n=124) Placebo (n=93) Veverimer (n=114) Placebo (n=82) Serious adverse events (none assessed to be related to study drug)* 2.4% 2.2% 1.8% 4.9% Discontinued study treatment 4.0% 4.3% 2.6% 9.8% Discontinued study due to an advers
Slide 21: Ongoing VALOR-CKD Renal Outcomes Trial
Ongoing VALOR-CKD Renal Outcomes Trial
Slide 22: VALOR-CKD Confirmatory Outcomes Trial
22 VALOR-CKD Confirmatory Outcomes Trial The trial is currently designed to terminate when the independent blinded Clinical Endpoint Adjudication Committee (CEAC) has positively adjudicated 511 subjects with primary efficacy endpoint events – Includes two interim analyses for early stopping for effi
Slide 23: VALOR-CKD Is Currently Adequately Powered for the Observed Treatment Effect
23 Tricida Believes VALOR-CKD Is Currently Adequately Powered for the Treatment Effect Observed in the TRCA-301/301E Trial * Post-hoc analysis of change from baseline in serum bicarbonate from TRCA-301/301E showed that the data were not normally distributed. Thus, the between-group difference of the
Slide 24: Interim Analyses Are Planned for Early Stopping for Efficacy
24 Interim Analyses Are Planned for Early Stopping for Efficacy • Interim alpha spending approach: O'Brien-Fleming alpha spending function – Nominal one-sided alpha required for significance at • Interim 1: 0.00004; observed HR will need to be < 0.50 • Interim 2: 0.00151; observed HR will need to be
Slide 25: Alternative Strategy to Stop VALOR-CKD Prior to the End of 2022 for Administrative Reasons
25 Alternative Strategy to Stop VALOR-CKD Trial Prior to the End of 2022 for Administrative Reasons True Hazard Ratio Administrative Stop at 150 Events Administrative Stop at 250 Events 0.76 39% Power 58% Power 0.70 59% Power 81% Power Observed Hazard Ratio Needed for Significance 0.72 Hazard Ratio
Slide 26: VALOR-CKD Primary Endpoint Event Tracking
26 VALOR-CKD Primary Endpoint Event Tracking Interim analysis 1: Anticipated 2H 2021 Interim analysis 2: Anticipated mid-2022 Final analysis: Anticipated 2024 VALOR-CKD anticipated event rates based on tracking against event rates observed in previous CKD trials * Data on event rates among 2197 cont
Slide 27: Tricida believes in the strength of the TRCA-301/301E data
27 • Tricida believes in the strength of the data from the TRCA-301/TRCA-301E trial, as published in The Lancet • Tricida believes that VALOR-CKD is adequately designed and is currently powered to confirm the clinical benefit of veverimer treatment in slowing CKD progression – Updated powering assum
Slide 28: Veverimer Market Opportunity
Veverimer Market Opportunity
Slide 29: Prevalence of Metabolic Acidosis and Estimated Patients Treated by Physician Type
29 3,000,000 Patients with CKD and metabolic acidosis 1,100,000 Diagnosed patients ~600,000 Nephrologist- treated patients Approval of Veverimer for Slowing of CKD Progression and/or Improving Physical Functioning Could Expand the Commercial Opportunity to Include Nephrologist- and PCP-treated Patie
Slide 30: Metabolic Acidosis Increases the Cost of Health Care
30 Analysis of Major Payer Database Shows Metabolic Acidosis Increases the Cost of Health Care Metabolic Acidosis Has a Significant Impact on Health Care Costs Optum® EMR, De-identified electronic medical records 2007–2017. Reaven N, Association of Managed Care Pharmacy; Oct 31, 2019 and ASN Kidney
Slide 31: Intellectual Property, Financial Position and Upcoming Milestones
Intellectual Property, Financial Position and Upcoming Milestones
Slide 32: New Veverimer Composition of Matter Patent Extends Patent Coverage to 2038
32 • Seven issued Orange Book eligible patents provide patent protection until 2038 • Several pending patent applications United States • Three issued EPO patents providing patent protection until 2034 and two additional issued patents providing protection until 2035 • Several pending EPO patent app
Slide 33: Financial Position
33 Financial Position • ~ $332 million cash, cash equivalents and investments as of December 31, 2020 • Debt includes: • $200 million of 3.50% Convertible Senior Notes due 2027 • $75 million currently drawn under a debt facility with Hercules - Current maturity of October 2023 - Extension to April 2
Slide 34: Key Veverimer Milestones
34*Veverimer is not yet approved by the FDA Key Veverimer Milestones* Obtained clarity on the path forward for resubmitting the veverimer NDA through the Accelerated Approval Program Conduct interim analysis 1 for potential early stopping of VALOR-CKD for efficacy Anticipated completion of VALOR-CKD
Slide 35: Thank You
THANK YOU IRICIDA